Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas

被引:92
作者
Tran, TA [1 ]
Kallakury, BVS [1 ]
Sheehan, CE [1 ]
Ross, JS [1 ]
机构
[1] ALBANY MED COLL, DEPT PATHOL & LAB MED, ALBANY, NY 12208 USA
关键词
CD44s; CD44v; non-small cell lung carcinoma; immunohistochemistry;
D O I
10.1016/S0046-8177(97)90154-4
中图分类号
R36 [病理学];
学科分类号
100104 [病理学与病理生理学];
摘要
CD44, a cell adhesion molecule, has been implicated in tumor invasion and metastasis in certain malignancies. We studied the expression of CD44 standard (CD44s) and variant isoforms (CD44v) in 98 non-small cell lung carcinomas (NSCLCs) by immunohistochemistry and correlated the observations with clinical outcome. Formalin-fixed, paraffin-embedded archival tissues from 49 squamous cell carcinomas (SCCs) and 49 adenocarcinomas (ACs) were immunostained after microwave irradiation with monoclonal antibodies against CD44s and CD44v3, v4/5, v6, v7/8, and v10, and the results were correlated with histological tumor type, tumor stage, recurrence, and survival rates. SCCs of the lung showed strong membranous expression of each of the CD44s, v3, v4/5, v6, and v10 proteins in comparison with ACs (P<.0001). Staining for CD44 v4/5 was overwhelmingly positive in SCCs (72%) as compared with ACs (2.2%). Intense immunoreactivity for CD44v6 was present in 19 of 20 (95%) metastatic lung carcinomas. The bronchiolar basal cells and alveolar pneumocytes were positive for CD44s, v3, and v6. CD44s and variant isoform expression did not correlate with tumor stage, recurrence, and survival rates. In conclusion, there is significant immunopositivity of CD44s and variant isoforms in SCCs over ACs of the lung. Expression of CD44v6 may suggest an increased risk for local lymph node metastasis in NSCLCs. CD44v4/5 reactivity may be useful to discriminate squamoid differentiation in poorly differentiated NSCLCs. HUM PATHOL 28:809-814. Copyright (C) 1997 by W.B. Saunders Company.
引用
收藏
页码:809 / 814
页数:6
相关论文
共 37 条
[1]
CD44 IS THE PRINCIPAL CELL-SURFACE RECEPTOR FOR HYALURONATE [J].
ARUFFO, A ;
STAMENKOVIC, I ;
MELNICK, M ;
UNDERHILL, CB ;
SEED, B .
CELL, 1990, 61 (07) :1303-1313
[2]
AUERBACH O, 1980, PULMONARY DISEASES D, P1388
[3]
HUMAN KERATINOCYTES EXPRESS A NEW CD44 CORE PROTEIN (CD44E) AS A HEPARAN-SULFATE INTRINSIC MEMBRANE PROTEOGLYCAN WITH ADDITIONAL EXONS [J].
BROWN, TA ;
BOUCHARD, T ;
STJOHN, T ;
WAYNER, E ;
CARTER, WG .
JOURNAL OF CELL BIOLOGY, 1991, 113 (01) :207-221
[4]
CARTER WG, 1988, J BIOL CHEM, V263, P4193
[5]
COMPARISON OF IMMUNOHISTOCHEMISTRY AND RT-PCR FOR DETECTION OF CD44V-EXPRESSION, A NEW PROGNOSTIC FACTOR IN HUMAN BREAST-CANCER [J].
DALL, P ;
HEIDER, KH ;
SINN, HP ;
SKROCHANGEL, P ;
ADOLF, G ;
KAUFMANN, M ;
HERRLICH, P ;
PONTA, H .
INTERNATIONAL JOURNAL OF CANCER, 1995, 60 (04) :471-477
[6]
Del Rosario A. D., 1994, Modern Pathology, V7, p73A
[7]
FUJITA N, 1994, CANCER RES, V54, P3922
[8]
A HUMAN-LYMPHOCYTE HOMING RECEPTOR, THE HERMES ANTIGEN, IS RELATED TO CARTILAGE PROTEOGLYCAN CORE AND LINK PROTEINS [J].
GOLDSTEIN, LA ;
ZHOU, DFH ;
PICKER, LJ ;
MINTY, CN ;
BARGATZE, RF ;
DING, JF ;
BUTCHER, EC .
CELL, 1989, 56 (06) :1063-1072
[9]
A NEW VARIANT OF GLYCOPROTEIN CD44 CONFERS METASTATIC POTENTIAL TO RAT CARCINOMA-CELLS [J].
GUNTHERT, U ;
HOFMANN, M ;
RUDY, W ;
REBER, S ;
ZOLLER, M ;
HAUSSMANN, I ;
MATZKU, S ;
WENZEL, A ;
PONTA, H ;
HERRLICH, P .
CELL, 1991, 65 (01) :13-24
[10]
HARN HJ, 1995, CANCER, V75, P1065, DOI 10.1002/1097-0142(19950301)75:5<1065::AID-CNCR2820750503>3.0.CO